An analysis of clinical trials shows that a single injected dose of the neuraminidase inhibitor (NAI) peramivir is safe and effective at alleviating influenza symptoms, including fever and viral shedding, when administered within 48 hours of the onset of symptoms, researchers said.
"Based on clinical data, peramivir is the first neuraminidase inhibitor (NAI) that has shown to be safe and effective as a single-dose therapy for patients with acute, uncomplicated influenza," said Rich Whitley of the University of Alabama at Birmingham.
In two placebo-controlled studies, involving a combined 427 adults, a single dose of peramivir was given as an injection within 48 hours of the onset of flu-like symptoms.
Study participants recorded their temperature and the severity of seven flu symptoms using a four-point scale for 14 days.
More From This Section
Peramivir was found to be generally safe and well tolerated and effectively reduced the duration of symptoms in peramivir-treated patients.
Compared to patients who received placebo, peramivir reduced median time to alleviation of symptoms by 22 hours, time to resolution of fever by 24 hours and the amount of nasal viral shedding over the first two days following treatment.
Vaccines can be effective in preventing influenza, but changing viral strains make vaccine formulation a challenge, and it is difficult to ensure broad populations are appropriately inoculated, they said.